Drug · CHEMBL1487
ATORVASTATIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ATORVASTATIN. Drugs and targets, record CHEMBL1487. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1487
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- ATORVASTATIN CALCIUM, ATORVASTATINA, ATORVASTATINE, Atorvastatina, Atorvastatine, CARDYL, LIPITOR, PREVENCOR, SORTIS, TAHOR, ZARATOR
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | HMG-CoA reductase inhibitor | INHIBITOR | https://conductscience.org/library/genes/3156 |
Source ChEMBL
Diseases154
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 154Source Open Targets
See all 154 diseasesTrials869
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02596126 | Secondary Prevention of Cardiovascular Disease in the Elderly Trial | Phase 3 | 2,499 | 2025-05-23 | atorvastatin | Its name | ClinicalTrials.gov |
| NCT00620542 | CRESTOR Athero Imaging Head to Head IVUS Study | Phase 3 | 2,333 | 2012-06-25 | atorvastatin | Its name | ClinicalTrials.gov |
| NCT01154036 | MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162) | Phase 3 | 1,547 | 2014-02-12 | atorvastatin | Its name | ClinicalTrials.gov |
| NCT00418834 | Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112) | Phase 3 | 1,053 | 2009-10-06 | atorvastatin | Its name | ClinicalTrials.gov |
| NCT01544309 | LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts | 1,049 | 2015-03-17 | atorvastatin | Its name | ClinicalTrials.gov | |
| NCT02662569 | Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia | Phase 3 | 986 | 2019-01-11 | atorvastatin | Its name | ClinicalTrials.gov |
| NCT00683618 | Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia | Phase 3 | 934 | 2012-03-12 | atorvastatin | Its name | ClinicalTrials.gov |
| NCT00249249 | Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels | Phase 3 | 830 | 2009-12-16 | atorvastatin | Its name | ClinicalTrials.gov |
| NCT00862251 | Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED) | Phase 3 | 808 | 2012-03-16 | atorvastatin | Its name | ClinicalTrials.gov |
| NCT00631189 | Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients | Phase 4 | 668 | 2010-09-17 | atorvastatin | Its name | ClinicalTrials.gov |
1 to 10 of 869
See all 869 trialsComparisons in its trials181
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Treatment Prevention for Secondary CV vs Cardiovascular Polypill: deaths from any cause | 117 of 1,229 | 115 of 1,237 | 2,466 | NCT02596126 | Trial comparisons |
| Treatment Prevention for Secondary CV vs Cardiovascular Polypill: serious adverse events | 220 of 1,229 | 248 of 1,237 | 2,466 | NCT02596126 | Trial comparisons |
| Without Concomitant Drugs vs With Concomitant Drugs: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Concomitant Drugs. | 3 of 360 | 15 of 885 | 1,245 | NCT01107743 | Trial comparisons |
| Male vs Female: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Gender. | 7 of 458 | 11 of 787 | 1,245 | NCT01107743 | Trial comparisons |
| Without Hypertension vs With Hypertension: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypertension. | 0 of 8 | 18 of 1,237 | 1,245 | NCT01107743 | Trial comparisons |
Without Hypercholesterolemia vs With Hypercholesterolemia: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Hypercholesterolemia. | 0 of 18 | 18 of 1,227 | 1,245 | NCT01107743 | Trial comparisons |
| Without Complications vs With Complications: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Complications. | 5 of 568 | 13 of 677 | 1,245 | NCT01107743 | Trial comparisons |
| <65 Years vs >=65 Years: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Age. | 5 of 377 | 13 of 868 | 1,245 | NCT01107743 | Trial comparisons |
| Without Angina Pectoris vs With Angina Pectoris: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Angina Pectoris. | 18 of 1,062 | 0 of 183 | 1,245 | NCT01107743 | Trial comparisons |
Without Familial Hypercholesterolemia vs With Familial Hypercholesterolemia: Risk Factors for Incidence Rate of Treatment Related Adverse Events(TRAEs) of Amlodipine/Atorvastatin Combination Tablets -Familial Hypercholesterolemia. | 18 of 1,231 | 0 of 14 | 1,245 | NCT01107743 | Trial comparisons |
1 to 10 of 181
See all 181 comparisons in its trialsPapers from its trials719
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials15
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Stroop Color-Word Test | 5 | 0 | ConductCognition |
| Verbal Learning | 4 | 2 | ConductCognition |
| Symbol Coding | 3 | 1 | ConductCognition |
| Trail Making Test A | 3 | 0 | ConductCognition |
| Trail Making Test B | 3 | 0 | ConductCognition |
| Verbal Fluency | 3 | 0 | ConductCognition |
| Attention Network Test | 1 | 0 | ConductCognition |
| Clock Drawing Task | 1 | 0 | ConductCognition |
| Complex Figure Copy and Recall | 1 | 0 | ConductCognition |
| Contrast Sensitivity Test | 1 | 0 | ConductCognition |
1 to 10 of 15
See all 15 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1487
GET https://conductscience.org/api/drugs/v1/CHEMBL1487/diseases?page=2